Physician profile
Richard C Lock
NPI 1558334219
$12,993.32
in general payments reported to CMS, 2019-2025
42 companies · $1,655 in 2025
The $1,655 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,180 · 2020: $2,071 · 2021: $2,006 · 2022: $1,735 · 2023: $1,706 · 2024: $1,640 · 2025: $1,655.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,001.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,279.49 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $1,554.62 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,379.76 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,126.77 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Abbvie INC. | $700.11 | 2021-2024 | |
| Lilly USA, LLC | $640.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $616.29 | 2019-2025 | Repatha, Krystexxa, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.31 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $532.64 | 2019-2022 | |
| Amarin Pharma, INC. | $491.96 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $472.08 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $287.82 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $283.02 | 2019-2023 | |
| Gilead Sciences, INC. | $275.18 | 2020-2025 | |
| Allergan, INC. | $271.31 | 2019-2020 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.